Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature

Lung Cancer

Volumn 108, Issue , 2017, Pages 217-221

  Ruiz Bañobre, Juan ^a   Pérez Pampín, Eva ^a   García González, Jorge ^a   Gómez Caamaño, Antonio ^a   Barón Duarte, Francisco Javier ^a   López López, Rafael ^a   Vázquez Rivera, Francisca ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Immune related adverse event; Immunotherapy; Nivolumab; Non small cell lung cancer; Programmed cell death 1; Psoriatic arthritis

Indexed keywords

CISPLATIN; FOLIC ACID; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NIVOLUMAB; PEMETREXED; SALAZOSULFAPYRIDINE; TRIAMCINOLONE ACETONIDE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADD ON THERAPY; ADULT; ANKYLOSIS; ARTHROCENTESIS; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DAS28; DRUG WITHDRAWAL; DYSPNEA; GENERAL CONDITION DETERIORATION; GENERAL CONDITION IMPROVEMENT; HEADACHE; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERTENSION; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAIL DYSTROPHY; NON SMALL CELL LUNG CANCER; OSTEOPENIA; PAROXYSMAL ATRIAL FIBRILLATION; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; COMPLICATION; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SKIN; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ARTHRITIS, PSORIATIC; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85018478651     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.04.007     Document Type: Article

References (36)

1. [1] Siegel, R., Miller, K., Jemal, A., Cancer statistics, 2017. CA. Cancer J. Clin. 67:1 (2017), 7–30.
2. [2] Travis, W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J.H.M., Beasley, M.B., et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 10:9 (2015), 1243–1260 ([Internet]. International Association for the Study of Lung Cancer).
3. [3] Leighl, N.B., Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr. Oncol. 19:Suppl. 1 (2012), S52–S58 (Internet]. Jun [cited 2015 Jul 4).
4. [4] Gerber, D.E., Schiller, J.H., Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J. Clin. Oncol. 31:8 (2013), 1009–1020 (Internet]. Mar 10 [cited 2015 Jul 4).
5. [5] Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-Cell non-Small-Cell lung cancer. N. Engl. J. Med., 2015, 373123–373135 (Massachusetts Medical Society; 2015).
6. [6] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer. N. Engl. J. Med. 373:17 (2015), 1627–1639 (Internet).
7. [7] Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2017), 1540–1550 ([Internet]. Elsevier; Mar 28).
8. [8] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. Pembrolizumab versus chemotherapy for PD-L1?Positive non?Small-Cell lung cancer. N. Engl. J. Med. 375:19 (2016), 1823–1833 ([Internet] Massachusetts Medical Society; 2016 Oct 8).
9. [9] Wolchok, J.D., Hoos, A., O'day, S., Weber, J.S., Hamid, O., Lebbé, C., et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. 2017.
10. [10] Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann. Oncol. 27:4 (2016), 559–574.
11. [11] Olivieri, I., D'Angelo, S., Palazzi, C., Padula, A., Advances in the management of psoriatic arthritis. Nat. Rev. Rheumatol. 10:9 (2014), 1–12 ([Internet]. Nature Publishing Group).
12. [12] Gladman, D.D., Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64:suppl._2 (2005), ii14–7 (Internet).
13. [13] Taylor, W., Gladman, D., Helliwell, P., Marchesoni, A., Mease, P., Mielants, H., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54:8 (2006), 2665–2673 (Internet]. Aug [cited 2016 Jun 28).
14. [14] Lubberts, E., The IL-23-IL-17 axis in inflammatory arthritis. Nat. Rev. Rheumatol. 11:7 (2015), 415–429 ([Internet]. Nature Publishing Group).
15. [15] Law-Ping-Man, S., Martin, A., Briens, E., Tisseau, L., Safa, G., Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology 55:11 (2016), 2087–2089 ([Internet]. Nov 1).
16. [16] De Velasco, G., Bermas, B., Choueiri, T.K., Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol., 68(2), 2016, 556.
17. [17] Cappelli, L.C., Gutierrez, A.K., Baer, A.N., Albayda, J., Manno, R.L., Haque, U., et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann. Rheum. Dis., 2016 (Internet]. Jun 15 [cited 2016 Jun 22).
18. [18] Salmon, J.-H., Lambrecht, I., Brochot, P., Grange, F., A case of arthritis under pembrolizumab. J. Bone Spine, 2016, 2–3 ([Internet]. Société française de rhumatologie).
19. [19] Gossec, L., Smolen, J.S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis., 2015 ([Internet]. Dec 7).
20. [20] Coates, L.C., Kavanaugh, A., Mease, P.J., Soriano, E.R., Laura Acosta-Felquer, M., Armstrong, A.W., et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol., 2016 ([Internet]. Mar [cited 2017 Mar 27]: n/a-n/a).
21. [21] Mease, P.J., Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle enthesitis index (MEI), leeds enthesit. Arthritis Care Res. (Hoboken) 63:S11 (2011), S64–S85 (Internet]. John Wiley & Sons, Inc. Nov [cited 2017 Mar 31).
22. [22] Fransen, J., Stucki, G., van Riel, P.L.C.M., Rheumatoid arthritis measures: disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Rheum. 49:S5 (2003), S214–24 (Internet).
23. [23] Mease, P.J., Antoni, C.E., Gladman, D.D., Taylor, W.J., Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis., 64(February (suppl 2)), 2005 ([Internet]. ii49 LP −ii54).
24. [24] Mease, P.J., Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle enthesitis index (MEI), leeds enthesit. Arthritis Care Res. (Hoboken) 63:November (S11) (2011), S64–S85 (Internet]. John Wiley & Sons, Inc. [cited 2017 Mar 27).
25. [25] Brown, P.M., Pratt, A.G., Isaacs, J.D., Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12:December (12) (2016), 731–742 ([Internet]. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved).
26. [26] Lena, H., Rizvi, N.A., Wolf, J., Cappuzzo, F., Zalcman, G., Baas, P., et al. 137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses. J. Thorac. Oncol. 11:March (4) (2017), S115–S116 ([Internet]. Elsevier).
27. [27] Barlesi, F., Steins, M., Horn, L., Ready, N., Felip, E., Borghaei, H., et al. Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. Ann. Oncol., 27(suppl._6), 2016 ([Internet]. Oct:1215PD −1215PD).
28. [28] Peled, M., Strazza, M., Azoulay-Alfaguter, I., Mor, A., Analysis of programmed death-1 in patients with psoriatic arthritis. Inflammation, 38(4), 2015.
29. [29] Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:19 (2010), 3167–3175.
30. [30] Mole, R.H., Whole body Irradiation—Radiobiology or medicine?*. Br. J. Radiol. 26:305 (1953), 234–241 ([Internet]. 1953 May [cited 2016 Jun 26]).
31. [31] Tefferi, A., Hiniker, S.M., Chen, D.S., Knox, S.J., Abscopal effect in a patient with melanoma. N. Engl. J. Med. 366:21 (2012), 2035–2036.
32. [32] Murata, S., Kaneko, S., Harada, Y., Aoi, N., Morita, E., Case of de novo psoriasis possibly triggered by nivolumab. J. Dermatol., 2016, 1–2.
33. [33] Corvellec, H., Kato, Y., Otsuka, A., Miyachi, Y., Kabashima, K., Matsumura, N., et al. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. Acta Derm. Venereol. 17:xx (2015), 1–2 (Internet).
34. [34] Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S.A., et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA dermatology 151:11 (2015), 1206–1212 (Internet).
35. [35] Bonigen, J., Raynaud-Donzel, C., Hureaux, J., Kramkimel, N., Blom, A., Jeudy, G., et al. Anti-PDI-induced psoriasis: a study of 21 patients. J Eur Acad Dermatology Venereol, 2016 ([Internet] n/a-n/a).
36. [36] Ruiz-Bañobre, J., Abdulkader, I., Anido, U., León, L., López-López, R., García-González, J., Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. APMIS 125:3 (2017), 259–263 (Internet).